Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel
April 14 2023 - 6:00AM
Business Wire
- MBT Mycobacteria IVD Kit optimizes sample preparation and
comprehensive library of MBT HT Mycobacteria IVD Module
- MBT HT Filamentous Fungi IVD Module incorporates extensive
fungal library with easy and effective sample preparation
(MyT)
- New MBT Compass HT IVD software significantly increases
speed for microbial identification, with unique automated
self-tuning
- New LiquidArray® Gastrointestinal PCR Panel detects 26
pathogens causing gastroenteritis, covering bacteria, viruses,
parasites and associated toxins
At the 33rd European Congress of Clinical Microbiology &
Infectious Diseases (www.eccmid.org), Bruker Corporation (Nasdaq:
BRKR) announced its latest innovations for user-friendly,
best-in-class diagnostic solutions for routine clinical
microbiology and infection diagnostics laboratories.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230414005018/en/
MALDI Biotyper® sirius (Photo: Business
Wire)
1. Bruker introduces fast next-generation MALDI Biotyper® IVD
Software
Microbial identification faster than ever: The MBT
Compass HT IVD software provides a high sample throughput for
microbial identification with time-to-result of ~5 minutes for 96
sample spots. Because of a fast sample target exchange, the MBT
system can now analyze up to 600 samples per hour, while covering
over 4,600 species in the reference library.
Microbial identification with optimal performance: The
new IDealTune™, part of the MBT Compass HT IVD software, provides
fully automated tuning of MALDI-TOF parameters within a sample run,
delivering consistent data quality without user intervention. This
seamless and effortless approach further increases performance,
reproducibility, and up-time of the system.
2. Optimizing sample preparation for mycobacteria
As mycobacteria are challenging species in microbiology, an
optimized sample preparation protocol is essential for robust
results. The new MBT Mycobacteria IVD Kit offers a user-friendly,
dedicated sample preparation method for mycobacteria cultivated in
liquid as well as on solid media. The inactivation method for safe
sample handling does not require boiling, but convenient incubation
of the mycobacteria with an inactivation reagent at room
temperature.
Dr. Arthur Pranada, Head of the Microbiology Division at MVZ Dr.
Eberhard & Partner in Dortmund, stated: “During the last years
the number of clinical samples with nontuberculous mycobacteria has
increased, and reliable identification is important for an
assessment of the clinical significance. The MBT Mycobacteria IVD
Kit further simplifies the workflow for identification of
nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on
time. During the evaluation in our laboratory more than 96% of
mycobacteria from solid and liquid media could be identified at a
high-confidence level.”
Identifying challenging filamentous fungi
Identifying molds and multicellular fungi remains one of the
most complex aspects of microbiology, because of varying culture
conditions and colony morphology. The new MBT HT Filamentous Fungi
IVD Module comes with an easy, yet powerful Mycelium Transfer (MyT)
sample preparation procedure which together with a comprehensive
reference library offers high identification success rates.
3. New LiquidArray® Gastrointestinal PCR Assay for Broad
Syndromic Testing
Rapid culture-free pathogen identification: Bruker’s
LiquidArray® technology offers rapid, multiplexed PCR pathogen
detection for ease of implementation. Launched on the
high-precision FluoroCycler® XT thermocycler, LiquidArray® combines
innovative probe and thermocycling technologies with
results-at-a-glance visualization for the simultaneous analysis of
multiple targets from a single sample. The integrated
FluoroSoftware® XT-IVD generates easy-to-interpret results,
accelerating clinical decisions. The new LiquidArray®
Gastrointestinal is a syndromic panel that enables the simultaneous
detection of up to 26 pathogens causing gastroenteritis.
LiquidArray® Gastrointestinal is validated on the GenoXtract® fleXT
which streamlines extraction and PCR. This provides high-throughput
clinical laboratories with a fully integrated workflow from sample
to result.
Dr. Wolfgang Pusch, President of the Bruker Microbiology &
Infection Diagnostics division, commented: “With the introduction
of our new IVD workflows, kits, software and reference libraries
for mycobacteria and fungi, we further expand the applications of
our established MALDI Biotyper® platform. This creates additional
value for all current and future customers. The new LiquidArray®
Gastrointestinal is a next-generation syndromic panel with amazing
pathogen coverage. It is ideal for laboratories which are
interested in a broad screening approach to detect most pathogens
in one run.”
To see Bruker’s technology in action, visit booth C3-15 at
ECCMID 2023, April 15-18 in Copenhagen, DK.
About the Bruker MALDI Biotyper® (MBT) platform The MBT
enables molecular identification of bacteria, yeasts and fungi.
Classification and identification of microorganisms is achieved
reliably and quickly using a molecular approach based on proteomic
fingerprinting by high-throughput MALDI-TOF MS. Applications
include clinical routine microbial identification, environmental
and pharmaceutical analysis, taxonomical research, food and
consumer product safety and quality control, as well as marine
microbiology. In many international laboratories, the MBT has
replaced classical biochemical testing for bacterial identification
due to its accuracy, speed, extensive species coverage, ease of
use, minimal sample preparation and cost-effectiveness. MBT
products are available in a research use only (RUO) version, as
general purpose (GP) version, as the U.S. FDA-cleared MBT CA
System, or in an IVD-CE version. The MBT also has IVD medical
device registrations in numerous other countries.
About the Bruker LiquidArray® technology The innovative
LiquidArray® technology optimizes asymmetrical multiplex PCR
for creating excess single-stranded amplicons with detection by
Lights-On/-Off probes that contain a quencher (Lights-Off) or both
fluorophore and quencher (Lights-On). If both probes are hybridized
in proximity on the amplicon, the quencher of the Lights-Off probe
eliminates the fluorescence emitted by the Lights-On probe. During
melting curve analysis, Lights-On/-Off probes detach from the
amplicon at specific temperatures. In the unbound state, Lights-On
probes cannot emit, and as fluorescence is either emitted or
suppressed, specific fluorescence signatures are generated by the
unique FluoroCycler® XT thermocycler for the LiquidArray®
multiplex PCR technology. The LiquidArray® technology
supports multiplexed assays where a large number of targets is
analyzed simultaneously from single samples. For example, the
LiquidArray®-powered, WHO-endorsed FluoroType® MTDBR VER 2.0
assay detects more than 500 genotypes by the combined analysis of
up to 45 different mutations in mycobacteria.
About Bruker Corporation (Nasdaq: BRKR) Bruker is
enabling scientists to make breakthrough discoveries and develop
new applications that improve the quality of human life. Bruker’s
high performance scientific instruments and high value analytical
and diagnostic solutions enable scientists to explore life and
materials at molecular, cellular and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity and customer success in life science
molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230414005018/en/
Investor Justin Ward Senior Director Investor Relations
and Corporate Development +1 (978) 663–3660, ext. 1479
investor.relations@bruker.com
Customer & media Philip Perry Bruker Microbiology
& Infection Diagnostics +49-172-313-7216
Philip.Perry@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024